Latest News and Press Releases

AUSTIN, Texas, July 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) today announced that the compensation committee of the Company’s board of directors approved an inducement...

AUSTIN, Texas, May 14, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced financial and business results for its first quarter fiscal year 2020 ended...

Principal Investigator Dr. Andrew Brenner to Lead Musella Foundation Live Webinar:“A Promising New Radiotherapy for Recurrent Glioblastoma” AUSTIN, Texas, May 12, 2020 (GLOBE NEWSWIRE) --...

AUSTIN, Texas, May 11, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”, “Plus”), today announced the closing of its previously announced definitive agreement to...

AUSTIN, Texas, May 07, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it will report its First Quarter Fiscal Year 2020 financial results after...

AUSTIN, Texas, April 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it is donating personal protective equipment to San Diego’s Scripps...

AUSTIN, Texas, April 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that Dr. Gregory Stein has joined the Company as Senior Vice President of...

AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”, “Plus”), today announced financial and business results for its Fourth Quarter and full...

Multiple Clinical & Preclinical Candidates for Rare Cancers, Including a Novel Radiotherapeutic for Glioblastoma AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc....

AUSTIN, Texas, March 25, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it will report its Fourth Quarter and full Fiscal Year 2019 financial...